INS and type 2 diabetes mellitus: A multicentre randomized parallel-group trial suggested that exenatide was more effective in improving β-cell function compared to insulin and piogltazone; hence, early initiation of β-cell-protective therapy with exenatide may halt the decline in β-cell function in type 2 diabetes [32].